CYTARABINE PLUS IDARUBICIN OR DAUNORUBICIN AS INDUCTION AND CONSOLIDATION THERAPY FOR PREVIOUSLY UNTREATED ADULT PATIENTS WITH ACUTE MYELOID-LEUKEMIA

被引：1
|
作者：
WIERNIK, PH
BANKS, PLC
CASE, DC
ARLIN, ZA
PERIMAN, PO
TODD, MB
RITCH, PS
ENCK, RE
WEITBERG, AB
机构：
[1] ADRIA LABS INC, COLUMBUS, OH USA
[2] MAINE MED CTR, PORTLAND, ME 04102 USA
[3] NEW YORK MED COLL, VALHALLA, NY 10595 USA
[4] HARRINGTON CANC CTR, AMARILLO, TX USA
[5] YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA
[6] MED COLL WISCONSIN, MILWAUKEE, WI 53226 USA
[7] RIVERSIDE CANC INST, COLUMBUS, OH USA
[8] ROGER WILLIAMS GEN HOSP, PROVIDENCE, RI 02908 USA
来源：
BLOOD | 1992年 / 79卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：313 / 319
页数：7
相关论文
共 50 条
  • [21] Role of daunorubicin in the induction therapy for adult acute myeloid leukemia
    Usui, N
    Dobashi, N
    Kobayashi, T
    Yano, S
    Maki, N
    Asai, O
    Saito, T
    Yamaguchi, Y
    Watanabe, H
    Kato, A
    Ogihara, A
    Katori, M
    Nagamine, M
    Takei, Y
    Yamazaki, H
    Funakoshi, S
    Tajima, N
    Ogawa, M
    Kuraishi, Y
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) : 2086 - 2092
  • [22] Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study
    Ohtake, Shigeki
    Miyawaki, Shuichi
    Fujita, Hiroyuki
    Kiyoi, Hitoshi
    Shinagawa, Katsuji
    Usui, Noriko
    Okumura, Hirokazu
    Miyamura, Koichi
    Nakaseko, Chiaki
    Miyazaki, Yasushi
    Fujieda, Atsushi
    Nagai, Tadashi
    Yamane, Takahisa
    Taniwaki, Masafumi
    Takahashi, Masatomo
    Yagasaki, Fumiharu
    Kimura, Yukihiko
    Asou, Norio
    Sakamaki, Hisashi
    Handa, Hiroshi
    Honda, Sumihisa
    Ohnishi, Kazunori
    Naoe, Tomoki
    Ohno, Ryuzo
    [J]. BLOOD, 2011, 117 (08) : 2358 - 2365
  • [23] Randomized clinical trial of induction therapy comparing intensified daunorubicin with idarubicin in patients with previously untreated de novo acute myeloid leukemia (JALSG AML201 study).
    Ohtake, Shigeki
    Miyawaki, Shuichi
    Fujita, Hiroyuki
    Kiyoi, Hitoshi
    Shinagawa, Katsuji
    Usui, Noriko
    Miyamura, Koichi
    Nishimura, Miki
    Miyazaki, Yasushi
    Nishii, Kazuhiro
    Nagai, Tadashi
    Yamane, Takahisa
    Taniwaki, Masafumi
    Takahashi, Masatomo
    Yagasaki, Fumiharu
    Kimura, Yukihiko
    Asou, Norio
    Honda, Sumihisa
    Ohnishi, Kazumori
    Naoe, Tomoki
    Ohno, Ryuzo
    [J]. BLOOD, 2006, 108 (11) : 566A - 566A
  • [24] A RANDOMIZED STUDY OF MITOXANTRONE PLUS CYTARABINE VERSUS DAUNOMYCIN PLUS CYTARABINE IN THE TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH ACUTE NONLYMPHOCYTIC LEUKEMIA
    PAVLOVSKY, S
    LLAVEN, JG
    MARTINEZ, MAG
    SOBREVILLA, P
    EPPINGERHELFT, M
    MARIN, A
    LOPEZHERNANDEZ, M
    FERNANDEZ, I
    RUBIO, ME
    IBARRA, S
    LLUESMA, M
    ARGUELLES, GR
    DEDIEGO, FJ
    [J]. ANNALS OF HEMATOLOGY, 1994, 69 (01) : 11 - 15
  • [25] Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia
    Bradstock, Kenneth F.
    Link, Emma
    Di Iulio, Juliana
    Szer, Jeff
    Marlton, Paula
    Wei, Andrew H.
    Enno, Arno
    Schwarer, Anthony
    Lewis, Ian D.
    D'Rozario, James
    Coyle, Luke
    Cull, Gavin
    Campbell, Phillip
    Leahy, Michael F.
    Hahn, Uwe
    Cannell, Paul
    Tiley, Campbell
    Lowenthal, Ray M.
    Moore, John
    Cartwright, Kimberly
    Cunningham, Ilona
    Taper, John
    Grigg, Andrew
    Roberts, Andrew W.
    Benson, Warwick
    Hertzberg, Mark
    Deveridge, Sandra
    Rowlings, Philip
    Mills, Anthony K.
    Gill, Devinder
    Bardy, Peter
    Campbell, Lynda
    Seymour, John F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (15) : 1678 - 1685
  • [26] DAT (DAUNORUBICIN, CYTARABINE, 6-THIOGUANINE) IN ACUTE MYELOID-LEUKEMIA
    REES, JKH
    HAYHOE, FGJ
    [J]. LANCET, 1978, 1 (8078): : 1360 - 1361
  • [27] Usefulness of a Medication Instruction Sheet for Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia
    Uchida, Mayako
    Mochizuki, Erika
    Ishida, Shigeru
    Ozawa, Nana
    Yonemitsu, Hiroko
    Ochiai, Hideki
    Nakamura, Hanae
    Kawashiri, Takehiro
    Kato, Koji
    Egashira, Nobuaki
    Akashi, Koichi
    Ieiri, Ichiro
    [J]. IN VIVO, 2023, 37 (02): : 924 - 932
  • [28] Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia
    Woelich, Susan K.
    Braun, James T.
    Schoen, Martin W.
    Ramlal, Reshma
    Freter, Carl E.
    Petruska, Paul J.
    Lionberger, Jack M.
    [J]. ANTICANCER RESEARCH, 2017, 37 (02) : 713 - 717
  • [29] Venetoclax Combined with Daunorubicin and Cytarabine (DAV) As Induction Therapy in De Novo Young Adult Acute Myeloid Leukemia
    Wang, Huafeng
    Mao, Liping
    Xie, Wanzhuo
    Tong, Hongyan
    Yang, Min
    Xu, Gaixiang
    Ye, Xiujin
    Lu, Ying
    Wei, Juying
    Mai, Wenyuan
    Zhou, De
    Jin, Jie
    Zhu, Hong-Hu
    [J]. BLOOD, 2021, 138
  • [30] Seven-days administration of daunorubicin with cytarabine in the intensified induction therapy for adult acute myeloid leukemia.
    Usui, N
    Dobashi, N
    Asai, O
    Maki, N
    Yano, S
    Watanabe, H
    Uno, S
    Osawa, H
    Yahagi, Y
    Katori, M
    Nagamine, M
    Yamaguchi, H
    Saito, T
    Kasama, K
    Hirano, A
    Tajima, N
    Kuraishi, Y
    [J]. BLOOD, 1998, 92 (10) : 213B - 213B
12345